Chemotherapy, targeted therapies costs and outcomes

Thematic Poster Session
Chairs: M. Cerna (Bratislava, Slovakia), M. Pesek (Plzen, Czech Republic)

Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer K. Mori, T. Kondo, Y. Kamiyama, K. Tominaga (Utsunomiya, Japan)
The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results F. El Ghani, K. W. Maas, N. J. Schloesser, F. M. Schramel (Nieuwegein, Utrecht, The Netherlands)
Small cell lung cancer patients and their responses to treatment A. Dirican, S. Findik, O. Uzun, A. Atici, L. Erkan (Kurupelit, Turkey)
Prolonged gemcitabine (GMC) infusion alone or with cisplatin (CDDP) in advanced NSCLC patients with stable disease (SD) after two cycles of chemotherapy including GMC 30 minutes infusion C. Tibaldi, A. Chella, I. Bernardini, F. Russo, G. Toma, F. Tempestini, A. M. Santolicandro, A. Falcone, N. Ambrosino (Livorno, Pisa, Italy)
Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy)
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer I. Spasova, E. Illichova, M. Marel (Prague, Hradec Kralove, Czech Republic)
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel D. Havel, P. Babackova, M. Pesek (Plzen, Czech Republic)
Induction chemotherapy before lung cancer resection: experiences and perspectives M. Pesek, V. Spidlen, P. Mukensnabl, M. Terl (Plzen, Czech Republic)
Rates of treatment response and median survival in advanced non small cell lung cancer patients F. Oztuna, Y. Bulbul, O. Aycicek, T. Ozlu (Trabzon, Turkey)
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations A. Dirican, S. Findik, O. Uzun, A. Atici, L. Erkan (Kurupelit, Turkey)
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) C. Mascaux, N. Iannino, T. Berghmans, A-P. Meert, J-P. Sculier (Brussels, Belgium; Lille, France)
Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease D. Ferreira, B. Parente, J. Cunha, A. Fernandes, H. Queiroga, A. Barroso, S. Conde (Vila Nova de Gaia, Braga, Porto, Vila Real, Portugal)
Therapeutic approach in patients above 65 years with lung cancer H. Ganchev, Y. Yanchev, D. Kalev, D. Petkova, M. Kokoshian, E. Dimitrova (Varna, Bulgaria)
Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer H. Miyazaki, S. Honda, S. Morita, Y. Ozawa, M. Nagayama, T. Hirata (Shizuoka, Japan)
Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival M. Pesek, G. Krakorova (Plzen, Czech Republic)
The cost of lung cancer in Turkey E. Cakir, C. Karlikaya (Edirne, Turkey)
Assessment of costs and outcomes of chemotherapy in an observational setting in patients with advanced NSCLC (ACTION) H. G. Bischoff, M. Thomas, M. Hamann, A. Kielhorn (Heidelberg, Münster, Bad Homburg, Germany; Windlesham, United Kingdom)